Show simple item record

FieldValueLanguage
dc.contributor.authorKeighley, Caitlin Livia
dc.date.accessioned2024-07-19T05:36:01Z
dc.date.available2024-07-19T05:36:01Z
dc.date.issued2023en_AU
dc.identifier.urihttps://hdl.handle.net/2123/32824
dc.descriptionIncludes publication
dc.description.abstractBackground Invasive fungal infections (IFIs) such as those caused by Candida species, the most common fungal pathogen, are associated with significant mortality despite advances in antifungal therapy and medical care. The aims of this thesis were to assess prevention in high-risk groups, examine the risk factors for candidaemia and its complications, and antifungal drug resistance. Methods The thesis employs a thesis-by-publication format, comprising four epidemiological studies followed by two laboratory-based studies. Findings In a retrospective single-centre analysis of itraconazole prophylaxis in acute myeloid leukaemia (AML), breakthrough IFI rate was low. A prospective multicentre, case-controlled study across Australia found that central venous access device (CVAD) use, end-organ failure, hepatobiliary or gastrointestinal surgery, urological instrumentation or catheterisation, intravenous drug use (IVDU) and carbapenem were risks factors for candidaemia. A case-cohort study identified age > 65 years, intensive care unit (ICU) admission, absence of prior surgery, haematological malignancy, chronic organ dysfunction, gastrointestinal or unidentifiable source and prior use of antibiotics for at least 10 days as associated with mortality, and established a predictive model. Shorter time to positivity (TTP) was associated with higher mortality, with species-specific differences. WGS of C. tropicalis demonstrated high-level fluconazole resistance present exclusively in isolates with ERG11 gene mutations in the homozygous form. An ERG3 deletion was associated with azole-resistance on comparison of two bloodstream isolates of C. albicans. Conclusions The thesis first provides support for the continued use of itraconazole prophylaxis for AML patients. The research contributed to the understanding of risk factors and outcomes associated with candidaemia and provided insights into the genomic characteristics associated with antifungal resistance.en_AU
dc.language.isoenen_AU
dc.subjectCandidaen_AU
dc.subjectinvasive fungal infectionsen_AU
dc.subjectantifungal drug resistanceen_AU
dc.subjectantifungal prophylaxisen_AU
dc.subjectcandidaemiaen_AU
dc.subjectimmunocompromised hosten_AU
dc.titleStudies into the epidemiology and management of invasive fungal infections with a focus on candidaemia and antifungal resistanceen_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Westmead Clinical Schoolen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorCHEN, SHARON
usyd.include.pubYesen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.